AKT1 and ovarian cancer: Research has shown that 7-difluromethoxyl-5,4′-di-n-octylgenistein (DFOG), a new synthetic genistein analogue that suppresses PI3K/AKT signaling (Figure 13) in vitro as well as in vivo, was more lethal in ovarian cancer cells when c-Myc was inhibited and linked to early-stage ovarian carcinoma [182].